Keywords
Diagnosis
Treatment
Research progress
Submitted : 2021-10-31
Accepted : 2021-11-15
Published : 2021-11-30
Abstract
Renal cell carcinoma (RCC) is one of the most common tumors of the urinary system. With the development of medical technology, the diagnostic rate and incidence of RCC are increasing year by year. This article reviews the latest research progress in the diagnosis and treatment of renal cell carcinoma.
References
Ou WL, Cai Q, Hu S, et al., 2020, Clinical Progress of Immunotherapy for Urogenital Tumors. Medical Review, 39(10): 1384-1389.
Dong D, Li H, Ji Z, et al., 2019, Etiological Analysis and Prevention of Common Urogenital Tumors. Basic Medicine & Clinics, 39(06): 904-907.
Walsh PC, Retik AB, Vaugh ED, et al., 2002, Campbell‘s Urology 8th Edition,WB Saunders Company, Philadelphia, 1-3886.
Lin Y, Lin N, Tang L, et al., 2020, Clinical Evaluation of Contrast-enhanced Ultrasound in the Differential Diagnosis of Benign and Malignant Renal Tumors. Chinese and Foreign Medical Research, 18(35): 79-81.
Yuan H, Wei J, Li J, et al., 2019, Clinical Diagnosis and Treatment Related Analysis of Parenchymal Infiltrating Carcinoma of Renal Pelvis. Henan Journal of Surgery, 25(03): 24-26.
Pei L, Wu Z, Yu D, 2020, Imaging Features and Application Value of Magnetic Resonance Imaging in the Diagnosis of Renal Cell Carcinoma. Chinese Disaster Rescue Medicine, 8(05): 263-265.
Pei L, Wu ZP, Yu DF, 2020, Imaging Characteristics and Application Value of Magnetic Resonance in Diagnosis of Renal Carcinoma. Chinese Journal of Disaster Relief Medicine, 8(05): 263-265.
Meng QC, Xia WL, Yan LL, et al., 2019, Diagnostic Value of 3.0 T MRI Sequence in Renal Cell Carcinoma Subtype. Magnetic Resonance Imaging, 10(02): 140-144.
Yao Z, Chen X, 2017, Application of B-ultrasound-Guided Percutaneous Renal Biopsy in the Diagnosis of Renal Tumors. Clinical Medical Research and Practice, 2(06): 75-76.
Liang J, Guo Y, Wu J, 2019, Clinical Comparison of Two Different Surgical Methods for Localized Renal Cell Carcinoma. World Compounding Medicine, 5(04): 151-153.
2021, FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma. News Release. FDA (Accessed January 22, 2021).
Yao ZQ, Chen CH, Zhang XX, et al., 2020, Surgical Treatment of Complex Renal Carcinoma: A Review. Journal of Minimally Invasive Urology, 9(04): 281-285.